In ischemic stroke, the third most frequent cause of mortality in industrialized countries,
therapeutic options have until now been limited to the first hours after disease onset. Cell
transplantation has emerged in various neurological disorders, including experimental
stroke, as a successful recovery-promoting approach also in the post-acute stroke phase.
However, before envisaging any translation into humans of such promising cell-based
approaches we still need to clarify:(i) the ideal cell source for transplantation,(ii) the most …